Article

Drug approved specifically for treating myelofibrosis

Author(s):

The Food and Drug Administration approved the new drug Jakafi (ruxolitinib) on Nov. 16 to treat intermediate or high-risk myelofibrosis. Myelofibrosis is a rare form of chronic leukemia, in which fibrous tissue develops in the bone marrow and slows blood cell-formation. Symptoms include an enlarged spleen, fever, night sweats, feeling full too soon and easy bruising or bleeding.Although there are other treatment methods, such as transfusion, transplantation, chemotherapy and surgery, Jakafi is the first drug specifically approved to treat the disorder, as well as the first approval for the JAK inhibitor drug class. Jakafi inhibits the enzymes Janus-associated kinase (JAK) 1 and 2, which are involved in regulating blood. The approval is based on two phase 3 trials, which evaluated 528 patients total. In the COMFORT-I trial, about 42 percent of patients on Jakafi experienced at least a 35 percent reduction in spleen volume compared with 0.7 percent on placebo. Similar results were achieved in improvement of other symptoms. The COMFORT-II trial also showed greater reduction in 35 percent of spleen volume after 4 months--28.5 percent for Jakafi versus 0 percent for the best available therapy. Results showing that Jakafi prolongs survival are expected to be presented at the American Society of Hematology annual meeting in December.Serious side effects include low platelet levels (thrombocytopenia), anemia, fatigue, dizziness and headache. Jakafi will cost $7,000 for a month's supply, or $85,000 a year, and the company already has a co-payment assistance program in place.For more details, visit jakafi.com or call 855-452-5234.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Image of doctor with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.